MedCity News June 23, 2024
Ascidian Therapeutics’ technology edits RNA to treat inherited disorders. While the startup’s lead internal program is for the retinal disorder Stargardt disease, its new R&D alliance with Roche will focus on developing RNA-editing therapies for neurological indications.
Biotechnology research has brought patients therapies made by editing DNA. Roche aims be part of the next wave of genetic medicines with a focus on RNA. Its latest move in this strategy is a partnership with Ascidian Therapeutics, a startup with technology that edits RNA to address multiple mutations driving a disease.
According to terms of the alliance announced this past week, Roche is paying $42 million up front for rights to use Ascidian’s RNA exon-editing technology for certain neurological targets. Specific targets...
Today's Sponsors
Today's Sponsor